Biologics in Crohn's disease: searching indicators for outcome.
New insights into the underlying mechanism of Crohn's disease is enabling the development of new therapies. Even though the mechanisms of these drugs have been studied extensively, reliable indicators for implementation of new biologic drugs are still needed. This review presents biologics in Crohn's disease focusing on efficacy, steroid sparing, mucosal healing and safety, including immunogenicity.
van der Woude
C Janneke
CJ
Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands. c.vanderwoude@erasmusmc.nl
Hommes
Daniel W
DW
D000818:Animals; D001688:Biological Products / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003424:Crohn Disease / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome
D001688:Biological Products